Evidence for efficacy is based on the results from the Study CK-301-101
Home World News FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Evidence for efficacy is based on the results from the Study CK-301-101
